Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|NRG-GI002||NRG||A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY011||NRG||A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z4099||ACSOG||A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)<br><br>||Adult CIRB - Late Phase Emphasis||Completed|
|GOG-0198||GOG||A Randomized Study of Tamoxifen Versus Thalidomide (NSC # 66847) in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer; Cancer of the Fallopian Tube; and Primary Peritoneal Carcinoma after First Line Chemotherapy||Adult CIRB - Late Phase Emphasis||Completed|
|S1507||SWOG||A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA9171||Alliance||Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-BR-0118||RTOG||A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC# 66847) Versus Conventional Radiation Therapy For Multiple Brain Metastases||Adult CIRB - Late Phase Emphasis||Completed|
|E2810||ECOG||Randomized; Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-90802||CALGB||Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091605||Alliance||A Randomized Phase II Study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone versus anti- PD1 antibody plus Stereotactic Body Radiation therapy in advanced Merkel Cell Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|